tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VSTM Stock Latest News

Verastem’s Strong Commercial Performance and Growth Potential Reinforce Buy Rating
RatingsVerastem’s Strong Commercial Performance and Growth Potential Reinforce Buy Rating
2d ago
VSTM
Verastem Oncology Reports Strong Q3 2025 Results
PremiumCompany Announcements
Verastem Oncology Reports Strong Q3 2025 Results
3d ago
VSTM
Verastem Inc’s Earnings Call: Strong Launch and Financial Outlook
PremiumCompany Announcements
Verastem Inc’s Earnings Call: Strong Launch and Financial Outlook
3d ago
VSTM
Verastem’s Strong Financial Performance and Strategic Developments Justify Buy Rating Despite Minor Concerns
PremiumRatings
Verastem’s Strong Financial Performance and Strategic Developments Justify Buy Rating Despite Minor Concerns
3d ago
VSTM
Verastem weakness appears overdone, says Mizuho
PremiumThe Fly
Verastem weakness appears overdone, says Mizuho
3d ago
VSTM
Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
PremiumThe FlyMidday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
3d ago
CZR
HTZ
Verastem reports Q3 adjusted EPS (54c), consensus (61c)
Premium
The Fly
Verastem reports Q3 adjusted EPS (54c), consensus (61c)
3d ago
VSTM
Verastem Reports Strong Q3 Revenue and Pipeline Progress
Premium
Company Announcements
Verastem Reports Strong Q3 Revenue and Pipeline Progress
3d ago
8K
VSTM
Verastem price target raised to $15 from $14 at Mizuho
PremiumThe Fly
Verastem price target raised to $15 from $14 at Mizuho
9d ago
VSTM
Is VSTM a Buy, Before Earnings?
PremiumPre-Earnings
Is VSTM a Buy, Before Earnings?
10d ago
VSTM
Verastem Reports Promising Phase 1/2a Trial Data
PremiumCompany Announcements
Verastem Reports Promising Phase 1/2a Trial Data
15d ago
8K
VSTM
Verastem announces encouraging data from ongoing phase 1/2a of VS-7375 dose
PremiumThe Fly
Verastem announces encouraging data from ongoing phase 1/2a of VS-7375 dose
15d ago
VSTM
Buy Rating Affirmed for Verastem’s VS-7375 Due to Promising Efficacy and Competitive Edge in KRAS G12D Inhibitors
PremiumRatingsBuy Rating Affirmed for Verastem’s VS-7375 Due to Promising Efficacy and Competitive Edge in KRAS G12D Inhibitors
17d ago
VSTM
Verastem data ‘best-in-class’ despite slight decline, says RBC Capital
Premium
The Fly
Verastem data ‘best-in-class’ despite slight decline, says RBC Capital
18d ago
VSTM
Verastem: GFH375 resulted in 41% ORR in Phase 1/2 study
Premium
The Fly
Verastem: GFH375 resulted in 41% ORR in Phase 1/2 study
18d ago
VSTM
Verastem Announces Promising Data from VS-7375 Study
PremiumCompany Announcements
Verastem Announces Promising Data from VS-7375 Study
18d ago
8K
VSTM
Verastem management to meet with Cantor
PremiumThe Fly
Verastem management to meet with Cantor
22d ago
VSTM
Verastem assumed with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Verastem assumed with an Overweight at Cantor Fitzgerald
22d ago
VSTM
Verastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic Outlook
PremiumRatings
Verastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic Outlook
2M ago
VSTM
Leerink says competitor data suggest promising view for Revolution’s zoldonrasib
PremiumThe FlyLeerink says competitor data suggest promising view for Revolution’s zoldonrasib
2M ago
RVMD
VSTM
Verastem Updates on Cancer Therapy Developments
Premium
Company Announcements
Verastem Updates on Cancer Therapy Developments
2M ago
8K
VSTM
Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?
Premium
Company Announcements
Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?
2M ago
VSTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >